Using Radiomics to Predict Neoadjuvant Chemotherapy Efficacy

Fujian Medical University

Status: Completed

Conditions: Gastric Cancer

Treatments: Other: response to neoadjuvant chemotherapy

Study type: Observational

Funder types: Other

Identifiers

NCT05465512

FMUUH-001

Details and patient eligibility

About

Neoadjuvant chemotherapy (NC) is an important treatment for advanced gastric cancer (AGC). However, tools that effectively predict the efficacy of NC before treatment are lacking. Computed tomography images before and after NC were used to construct a deep learning-based radiomics signature to predict the efficacy of NC, prognoses and postoperative adjuvant chemotherapy benefit.

Full description

Background: Neoadjuvant chemotherapy (NC) is an important treatment for advanced gastric cancer (AGC). However, tools that effectively predict the efficacy of NC before treatment are lacking.

Methods: Computed tomography images before and after NC were used to construct a deep learning-based radiomics signature to predict the efficacy of NC, prognoses and postoperative adjuvant chemotherapy benefit. Tumor regression grade (TRG) =0 or 1 was defined as a good response to neoadjuvant chemotherapy (GRNC), and TRG=2 or 3 was defined as a poor response to neoadjuvant chemotherapy (PRNC). 193 patients with AGC from January 2010 to December 2018 in two different China university hospitals were included in this study. The before neoadjuvant chemotherapy imaging scoring system (BNCISS), imaging change scoring system before and after neoadjuvant chemotherapy (ICSS), which were constructed based on computed tomography images before after treatment.

Enrollment: 193 patients

Sex: All

Ages: 18 to 85 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Prospective collection and a retrospective analysis of patients seen from January 2010 to December 2018 at Fujian Medical University Union Hospital (FMUUH) and the First Hospital of Lanzhou University (FHLU) who were diagnosed with gastric adenocarcinoma and underwent radical resection

Exclusion criteria

• Patients with concurrent malignant disease, distant metastases, palliative resection, or gastric stump cancer were excluded.

Trial design

193 participants in 2 patient groups

good response to neoadjuvant chemotherapy (GRNC)

Description:

Tumor regression grade (TRG) =0 or 1 was defined as a good response to neoadjuvant chemotherapy (GRNC)

Treatment:

Other: response to neoadjuvant chemotherapy

poor response to neoadjuvant chemotherapy (PRNC)

Description:

TRG=2 or 3 was defined as a poor response to neoadjuvant chemotherapy (PRNC).

Treatment:

Other: response to neoadjuvant chemotherapy